Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19227585 | PHARMACEUTICAL COMPOSITION COMPRISING SUTTERELLA WADSWORTHENSIS AND IMMUNE CHECKPOINT INHIBITORS FOR TREATMENT OF COLON CANCER | June 2025 | January 2026 | Allow | 7 | 1 | 0 | No | No |
| 18624353 | ANTI-STAPHYLOCOCCUS AUREUS SPECIFIC ANTIBODY AND NUCLEIC ACID ENCODING SEQUENCE THEREOF, AND USES OF THE SAME | April 2024 | March 2025 | Allow | 12 | 1 | 1 | No | No |
| 18416083 | LACTOBACILLUS PARACASEI GLU70 STRAIN WITH GLUTEN-DEGRADING ABILITY AND ANTIBACTERIAL ACTIVITY AND PROBIOTIC PROPERTIES AND USES THEREOF | January 2024 | March 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18503901 | LYOPHILIZED AND STABILIZED LIVE ATTENUATED FORMULATED VACCINE AGAINST TULAREMIA | November 2023 | March 2025 | Allow | 16 | 2 | 0 | Yes | No |
| 18354838 | METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE SYSTEM FUNCTION | July 2023 | December 2025 | Abandon | 29 | 1 | 1 | No | No |
| 18249626 | BACTERIA BASED PROTEIN DELIVERY | April 2023 | September 2025 | Allow | 28 | 0 | 0 | Yes | No |
| 18147627 | IMMUNOTHERAPEUTIC VACCINE AND ANTIBODY COMBINATION THERAPY | December 2022 | September 2025 | Allow | 33 | 2 | 1 | Yes | No |
| 17910263 | PROTECTIVE STAPHYLOCOCCAL EXOTOXIN VACCINE | September 2022 | December 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17793813 | RECOMBINANT BCG, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | July 2022 | February 2026 | Allow | 43 | 1 | 1 | No | No |
| 17790103 | LASSO PEPTIDES FOR TREATMENT OF CANCER | June 2022 | October 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17789300 | ANTICANCER COMPOSITION COMPRISING TLR5 AGONIST DERIVED FROM FLAGELLIN AS ACTIVE INGREDIENT | June 2022 | January 2026 | Abandon | 43 | 2 | 0 | No | No |
| 17788137 | SAMPLE PREPARATION AND MICROBIAL ANALYSIS | June 2022 | September 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17786129 | LIVE ATTENUATED LEISHMANIA PARASITE VACCINES WITH ENHANCED SAFETY CHARACTERISTICS | June 2022 | February 2026 | Allow | 44 | 2 | 1 | Yes | No |
| 17783379 | M. TUBERCULOSIS AG85 PROTEINS AND METHODS OF USE | June 2022 | September 2025 | Abandon | 39 | 1 | 1 | No | No |
| 17782873 | TOOLS AND METHODS TO DETECT AND ISOLATE COLIBACTIN PRODUCING BACTERIA | June 2022 | September 2025 | Abandon | 39 | 1 | 1 | No | No |
| 17781930 | Bacterial strain Bacillus mojavensis PS17 for producing higher yield and protection of agricultural plants against phytopathogenic fungi | June 2022 | November 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17773494 | IMMUNOTHERAPY WITH COMBINATION THERAPY COMPRISING AN IMMUNOTOXIN | April 2022 | August 2025 | Allow | 40 | 2 | 0 | No | No |
| 17771175 | TREATMENT AND CONTROL OF BACTERIAL AND FUNGAL DISEASE IN HONEYBEES | April 2022 | October 2025 | Abandon | 42 | 1 | 1 | No | No |
| 17766551 | METHOD FOR TREATING AND/OR PREVENTING A PARASITIC INFECTION IN A TELEOST | April 2022 | February 2026 | Allow | 46 | 2 | 0 | No | No |
| 17765428 | NON-TOXIC LISTERIOLYSIN O POLYPEPTIDES AND USES THEREOF | March 2022 | March 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17438515 | Epitope-Based Approach for Allergy Treatments and Inhibitors for Crohn's Disease | September 2021 | September 2025 | Allow | 48 | 1 | 1 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner MORGAN, BAILEY MICHELLE works in Art Unit 1645 and has examined 1 patent applications in our dataset. With an allowance rate of 100.0%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 48 months.
Examiner MORGAN, BAILEY MICHELLE's allowance rate of 100.0% places them in the 94% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by MORGAN, BAILEY MICHELLE receive 1.00 office actions before reaching final disposition. This places the examiner in the 8% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by MORGAN, BAILEY MICHELLE is 48 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 200.0% of allowed cases (in the 100% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.